Shield Therapeutics appoints finance chief
pharmafile | May 16, 2011 | Appointment | Sales and Marketing | appointment, sales and marketing
Swiss specialty pharma company Shield Therapeutics has appointed Richard Jones to the newly-created role of chief financial officer.
He has more than 12 years of corporate finance and broking experience and was most recently director and head of healthcare at Brewin Dolphin Investment Banking.
Richard has been working closely with Shield’s management team as a non-executive director and member of the company’s board since early 2010, having previously been retained as an advisor to the management team since 2008.
Shield’s chief executive Carl Sterritt said: “We are delighted to welcome Richard to Shield’s management team at this important time in the Company’s development. Richard brings to Shield significant investment banking and strategic financial management experience, with a strong commercial focus.
“We look forward to him quickly becoming a pivotal member of our highly experienced team as we prepare to initiate late-stage clinical trials for ST10-021, our lead product for the treatment of iron deficiency anaemia.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






